Bruker Daltonics Announces Selection of its RAID-M Chemical Agent Detector for United States National Guard Program.

BILLERICA, Mass. -- Bruker Daltonics today announces that prior to the end of 2006, it has received a $1.7 million subcontract award for its RAID[TM]-M handheld chemical agent detectors from the US Army through a Lead Systems Integrator. Bruker Daltonics is expected to deliver most of the systems by the end of 2007. The systems are intended for the National Guard WMD Civil Support Teams' (CST) Analytical Laboratory System (ALS). The RAID-M will provide real-time chemical screening on site for the CST response mission.

Mr. Frank Thibodeau, Vice President of Bruker Daltonics NBC Detection Corp., commented: "We are very pleased with our selection for this critical National Guard program. This contract is just more evidence that the RAID-M has arguably become the preeminent handheld chemical agent detector in the world today with a detection performance and versatility not commonly expected of a handheld instrument. The National Guard ALS mission will span two important applications, in both defense and homeland security."

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc., Bruker AXS Inc. and Bruker Optics Inc. For more information, please visit www.bruker-biosciences.com

* Bruker AXS is a leading developer and provider of advanced X-ray tools used primarily in life science and materials research, as well as of X-ray and OES elemental analysis instrumentation used primarily in industrial applications.

* Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry and also develops and provides a broad range of field analytical systems for chemical, biological, radiological and nuclear detection.

* Bruker Optics is a leading developer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2005, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.